.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The global rise of antifungal drug resistance has necessitated the search for novel therapeutic agents. Consequently, researchers are turning toward extreme environments like the deep sea to discover bioactive molecules. A recent study has identified several previously undescribed compounds from the fungus Acremonium sclerotigenum. Notably, one specific isolate, compound 9, demonstrated remarkable efficacy against drug-resistant Candida auris. This pathogen frequently resists existing treatments and causes high mortality in clinical settings worldwide.
Researchers isolated nine compounds from the Acremonium sclerotigenum LW14 culture. They characterized these structures using detailed spectroscopic studies and calculations. Specifically, compound 9 emerged as a potent candidate with a Minimum Inhibitory Concentration (MIC) of 4 \u03bcg/mL against C. auris 12766. Furthermore, the molecule displayed low hemolytic toxicity, which suggests a favorable safety profile for future clinical development. Therefore, this compound represents a promising lead for pharmaceutical advancement.
Additionally, the study explored the underlying mechanism of action. Compound 9 appears to disrupt the fungal cell membrane and trigger the accumulation of intracellular reactive oxygen species (ROS). Moreover, it effectively inhibits the formation of biofilms, which often contribute to persistent hospital-acquired infections. Specifically, these findings highlight the potential of deep-sea meroterpenoids in diversifying our antimicrobial arsenal against antifungal drug resistance. Consequently, this discovery may lead to more effective management of multi-drug resistant fungal outbreaks.
Candida auris is a multidrug-resistant yeast that survives on surfaces and spreads rapidly in hospital environments. Consequently, it causes severe invasive infections with high mortality rates, particularly in immunocompromised patients.
Organisms in extreme deep-sea environments produce unique secondary metabolites. These molecules, such as the meroterpenoids found in Acremonium sclerotigenum, often possess novel chemical structures and mechanisms that bypass existing resistance pathways.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Huo R et al. Antifungal meroterpenoids from deep-sea-derived fungus Acremonium sclerotigenum. Phytochemistry. 2026 May 25. doi: undefined. PMID: 42184474.
Centers for Disease Control and Prevention (CDC). Candida auris: A drug-resistant germ that spreads in healthcare facilities. 2023.
World Health Organization (WHO). Fungal priority pathogens list to guide research, development and public health action. 2022.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Deep-sea-derived compounds show potent activity and low toxicity against drug-resistant Candida auris, representing a breakthrough in antifungal research....
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
